agilon health stock performance snapshot

agilon health (AGL) has drawn attention after a sharp move in its share price over the past month, prompting investors to reassess how its returns and financial profile line up with expectations.

Over the past month, the stock shows a 2.13% return, with a 7.12% gain over the past 3 months and a 64.52% total return over the past year. Year to date, the stock is up 4.50%, while the 3 year and 5 year total returns indicate substantial declines.

The company’s market value stands at about US$1.54b, with revenue of US$5,820.254m and a reported net loss of US$373.543m. Annual revenue growth is 7.60%, and annual net income growth is very large, reflecting movement off a low earnings base rather than steady profitability.

agilon health focuses on healthcare services for seniors through primary care physicians in the United States, using a subscription style per member per month model. For readers comparing quality and price, the stock currently carries a value score of 5 and trades at a significant discount to one intrinsic valuation estimate, with an indicated 74.03% gap.

The recent move to a US$92.54 share price sits on top of very strong short term share price momentum, contrasted with deeply negative multi year total shareholder returns. This highlights how quickly sentiment around agilon health has shifted.

If agilon health’s sharp rebound has you rethinking where the next opportunity might come from, this is a good moment to scan for other healthcare names shaping the future of AI with the 40 healthcare AI stocks

With agilon health trading at US$92.54, while one intrinsic estimate points to a large discount and the analyst price target sits lower, you need to ask: is this a mispriced rebound, or is the market already banking on future growth?

Most Popular Narrative: 371% Overvalued

The most followed narrative puts agilon health’s fair value at $19.67, far below the recent $92.54 close. This sets up a sharp valuation gap for investors to unpack.

The accelerating growth of the senior population and increasing prevalence of complex, chronic conditions, especially among the 80+ age group, are fueling multi-year demand for agilon health's model focused on comprehensive, value-based primary care for seniors. This demographic shift is expected to materially expand patient volumes and recurring revenues over time.

It may raise questions how a business still reporting losses is marked at this fair value. The story leans heavily on revenue expansion, margin repair, and a very lean future earnings multiple.

Result: Fair Value of $19.67 (OVERVALUED)

However, the narrative still hinges on agilon health turning around persistent losses while managing payer concentration risk. Any stumble on either front could quickly test this valuation gap.

Another angle on valuation

That $19.67 fair value from the narrative conflicts with Simply Wall St’s own cash flow view. The SWS DCF model points to a fair value of about $356.38 per share, with AGL at $92.54. This suggests the stock is trading at a steep discount. Which story do you trust more?

Next Steps

With such a mixed picture on value and sentiment, it pays to move quickly, review the numbers yourself, and decide what really matters for your portfolio by weighing the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If agilon health has sharpened your focus, this is the moment to widen your watchlist and line up a few fresh ideas before the next move catches you off guard.

• Target value opportunities by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying business strength.
• Prioritise resilience by reviewing 62 resilient stocks with low risk scores that aim to keep volatility and risk scores in check while still offering meaningful exposure to equities.
• Get ahead of the crowd by combing through the screener containing 22 high quality undiscovered gems that many investors may not yet be watching closely.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.